FLUOROPHARMA MEDICAL, INC. - FORM 10-K - EX-23.1 - CONSENT OF WOLF & COMPANY, P.C.

Attached files

file	filename
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 1350. - FLUOROPHARMA MEDICAL, INC.	ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.	ex31-2.htm
10-K - FORM 10-K - FLUOROPHARMA MEDICAL, INC.	fpmi10k_dec312015.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.	ex31-1.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 1350. - FLUOROPHARMA MEDICAL, INC.	ex32-2.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statement (No. 333-185648) on Form S-8 of FluoroPharma Medical, Inc. of our report dated March 30, 2016, relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of FluoroPharma Medical, Inc. for the year ended December 31, 2015. Our report dated March 30, 2016, relating to the consolidated financial statements includes an emphasis paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.

/s/ Wolf & Company, P.C.

Boston, Massachusetts

March 30, 2016

Attached files

FLUOROPHARMA MEDICAL, INC. Reports

Also read